Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Psychiatry Res

Retrieve available abstracts of 190 articles:
HTML format

Single Articles

    December 2022
  1. MANNARINI S, Taccini F, Sato I, Rossi AA, et al
    Understanding stigma toward schizophrenia.
    Psychiatry Res. 2022;318:114970.
    PubMed     Abstract available

    November 2022
    Social anhedonia and other indicators of risk for schizophrenia: Theory and inquiry.
    Psychiatry Res. 2022;319:114966.
    PubMed     Abstract available

  3. LV H, Li J, Gao K, Zeng L, et al
    Identification of genetic loci that overlap between schizophrenia and metabolic syndrome.
    Psychiatry Res. 2022;318:114947.
    PubMed     Abstract available

  4. RUIZ-DELGADO I, Moreno-Kustner B, Garcia-Medina M, Barrigon ML, et al
    Is Metacognitive Training effective for improving neurocognitive function in patients with a recent onset of psychosis?
    Psychiatry Res. 2022;318:114941.
    PubMed     Abstract available

    Genetic variation and susceptibility to schizophrenia: Work in progress.
    Psychiatry Res. 2022;318:114949.
    PubMed     Abstract available

  6. ZHANG Q, Huo JH, Guo L, Wang L, et al
    Common and rare variants within SP4 exert distinct molecular mechanisms contributing to the risk of schizophrenia.
    Psychiatry Res. 2022;318:114948.

  7. LU W, Srijeyanthan J, Mueser KT, Yanos PT, et al
    Predictors of undocumented PTSD in persons using public mental health services.
    Psychiatry Res. 2022;317:114892.
    PubMed     Abstract available

  8. KIM WS, Heo DW, Shen J, Tsogt U, et al
    Altered functional connectivity in psychotic disorder not otherwise specified.
    Psychiatry Res. 2022;317:114871.
    PubMed     Abstract available

  9. LANGLOIS T, Sanchez-Rodriguez R, Bourcier A, Lamy P, et al
    "Accept voices(c)" group intervention for the management of auditory verbal hallucinations-results at 6 and 12 months.
    Psychiatry Res. 2022;317:114860.
    PubMed     Abstract available

  10. RIHAL V, Khan H, Kaur A, Singh TG, et al
    Therapeutic and mechanistic intervention of vitamin D in neuropsychiatric disorders.
    Psychiatry Res. 2022;317:114782.
    PubMed     Abstract available

    October 2022
  11. ZHANG T, Zeng J, Wei Y, Ye J, et al
    Changes in inflammatory balance correlates with conversion to psychosis among individuals at clinical high-risk: A prospective cohort study.
    Psychiatry Res. 2022;318:114938.
    PubMed     Abstract available

  12. SCHELIGA S, Schwank R, Scholle R, Habel U, et al
    A neural mechanism underlying predictive visual motion processing in patients with schizophrenia.
    Psychiatry Res. 2022;318:114934.
    PubMed     Abstract available

  13. CUESTA MJ, Sanchez-Torres AM, Moreno-Izco L, Garcia de Jalon E, et al
    Neurocognitive correlates of the varied domains of outcomes at 20 year follow-up of first-episode psychosis.
    Psychiatry Res. 2022;318:114933.
    PubMed     Abstract available

  14. ENDRES D, Lerchenmuller V, Runge K, von Zedtwitz K, et al
    Anti-astrocytic autoantibody patterns in the cerebrospinal fluid of patients with depression and psychosis.
    Psychiatry Res. 2022;317:114905.
    PubMed     Abstract available

  15. GIZDIC A, Baxter T, Barrantes-Vidal N, Park S, et al
    Loneliness and psychosocial predictors of psychosis-proneness during COVID-19: Preliminary findings from Croatia.
    Psychiatry Res. 2022;317:114900.
    PubMed     Abstract available

  16. DEAN B, Thomas EHX, Bozaoglu K, Tan EJ, et al
    Evidence that a working memory cognitive phenotype within schizophrenia has a unique underlying biology.
    Psychiatry Res. 2022;317:114873.
    PubMed     Abstract available

  17. PELIZZA L, Quattrone E, Leuci E, Paulillo G, et al
    Anxious-depressive symptoms after a first episode of schizophrenia: Response to treatment and psychopathological considerations from the 2-year "Parma Early Psychosis" program.
    Psychiatry Res. 2022;317:114887.
    PubMed     Abstract available

  18. BARLATI S, Nibbio G, Bianchi F, Gigli EBL, et al
    Long-acting Injectable Antipsychotics during the COVID-19 pandemic in schizophrenia: An observational study in a real-world clinical setting.
    Psychiatry Res. 2022;317:114878.
    PubMed     Abstract available

  19. DOKUZ G, Kani AS, Uysal O, Kuscu MK, et al
    The impact of childhood trauma and daily life experiences on emotional and psychotic symptom intensity in psychosis: An experience sampling study.
    Psychiatry Res. 2022;317:114872.
    PubMed     Abstract available

    September 2022
    From co-morbidity to transdiagnostic potential and novel immunotherapies for psychosis.
    Psychiatry Res. 2022;317:114866.
    PubMed     Abstract available

  21. MORITZ S, Goritz AS, Franz C, Sibilis A, et al
    Whodunit - A novel video-based task for the measurement of jumping to conclusions in the schizophrenia spectrum.
    Psychiatry Res. 2022;317:114862.
    PubMed     Abstract available

  22. WALKER E
    The permeable boundary between biological and psychological processes in the origins of psychosis.
    Psychiatry Res. 2022;317:114853.
    PubMed     Abstract available

    A sisters search for the seeds of psychosis.
    Psychiatry Res. 2022;317:114846.
    PubMed     Abstract available

  24. SNELLEKSZ M, Rossell SL, Gibbons A, Nithianantharajah J, et al
    Evidence that the frontal pole has a significant role in the pathophysiology of schizophrenia.
    Psychiatry Res. 2022;317:114850.
    PubMed     Abstract available

  25. YAO L, Liu H, Tian X
    Medication adherence among community-dwelling schizophrenia patients during the COVID-19 pandemic: A cross-sectional study.
    Psychiatry Res. 2022;317:114841.
    PubMed     Abstract available

    August 2022
  26. KOOPOWITZ SM, Cotton SM, Uhlmann A, Thomas KGF, et al
    Executive function in methamphetamine users with and without psychosis.
    Psychiatry Res. 2022;317:114820.
    PubMed     Abstract available

  27. BIZUMIC B, Gunningham B, Christensen BK
    Prejudice towards people with mental illness, schizophrenia, and depression among mental health professionals and the general population.
    Psychiatry Res. 2022;317:114817.
    PubMed     Abstract available

  28. EATON WW, Rodriguez KM, Thomas MA, Johnson J, et al
    Immunologic profiling in schizophrenia and rheumatoid arthritis.
    Psychiatry Res. 2022;317:114812.
    PubMed     Abstract available

  29. BARANOVA A, Cao H, Zhang F
    Severe COVID-19 increases the risk of schizophrenia.
    Psychiatry Res. 2022;317:114809.
    PubMed     Abstract available

  30. MCCARTHY JM, Wood AJ, Shinners MG, Heinrich H, et al
    Pilot development and feasibility of telehealth Community Reinforcement and Family Training (CRAFT) for early psychosis and substance use.
    Psychiatry Res. 2022;317:114804.
    PubMed     Abstract available

  31. HU M, Xia Y, Zong X, Sweeney JA, et al
    Risperidone-induced changes in DNA methylation in peripheral blood from first-episode schizophrenia patients parallel changes in neuroimaging and cognitive phenotypes.
    Psychiatry Res. 2022;317:114789.
    PubMed     Abstract available

  32. LYNCH DA, Brown M, Saperstein A, Stefancic A, et al
    Assessing metamotivation in schizophrenia: A pilot study of the Brief Regulation of Motivation Scale (BRoMS).
    Psychiatry Res. 2022;317:114799.
    PubMed     Abstract available

  33. LI Z, Chen X
    Comprehensive analysis of shared genetic loci between hippocampal volume and schizophrenia.
    Psychiatry Res. 2022;316:114795.
    PubMed     Abstract available

  34. TIKKANEN V, Siira V, Wahlberg KE, Hakko H, et al
    Deficits in adolescent social functioning, dysfunctional family processes and genetic risk for schizophrenia spectrum disorders as risk factors for later psychiatric morbidity of adoptees.
    Psychiatry Res. 2022;316:114793.
    PubMed     Abstract available

  35. LIU CM, Liu CC, Hsieh MH, Hwang TJ, et al
    The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis.
    Psychiatry Res. 2022;316:114775.
    PubMed     Abstract available

  36. HERPERTZ J, Richter MF, Barkhau C, Storck M, et al
    Symptom monitoring based on digital data collection during inpatient treatment of schizophrenia spectrum disorders - A feasibility study.
    Psychiatry Res. 2022;316:114773.
    PubMed     Abstract available

  37. CAI H, Zeng C, Zhang X, Liu Y, et al
    Diminished treatment response in relapsed versus first-episode schizophrenia as revealed by a panel of blood-based biomarkers: A combined cross-sectional and longitudinal study.
    Psychiatry Res. 2022;316:114762.
    PubMed     Abstract available

  38. KOOL L, Oranje B, Meijs H, De Wilde B, et al
    Event-related potentials and use of psychotropic medication in major psychiatric disorders.
    Psychiatry Res. 2022;314:114637.
    PubMed     Abstract available

  39. PUJOL N, Berge D, Mane A, Bioque M, et al
    The influence of modifiable cardiovascular risk factors on cognition, functioning, and inflammatory markers in first-episode psychosis: Results from a 2-year follow-up study.
    Psychiatry Res. 2022;316:114760.
    PubMed     Abstract available

    July 2022
  40. SALEHI A, Namaei P, TaghaviZanjani F, Bagheri S, et al
    Adjuvant palmitoylethanolamide therapy with risperidone improves negative symptoms in patients with schizophrenia: A randomized, double-blinded, placebo-controlled trial.
    Psychiatry Res. 2022;316:114737.
    PubMed     Abstract available

  41. DESAI SS, Nguyen AL, Bernstein GA
    Letter to editor: Case report of long COVID-19 with psychosis in a child.
    Psychiatry Res. 2022;316:114743.

    Sex/Gender differences in schizophrenia: Thinking back and thinking forward.
    Psychiatry Res. 2022;316:114738.
    PubMed     Abstract available

  43. DADERWAL MC, Sreeraj VS, Suhas S, Rao NP, et al
    Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST) as a screening tool for evaluation of cognitive deficits in schizophrenia.
    Psychiatry Res. 2022;316:114731.
    PubMed     Abstract available

  44. GALLIOT G, Sanchez-Rodriguez R, Belloc A, Phulpin H, et al
    Is clinical insight a determinant factor of subjective recovery in persons living with schizophrenia or schizoaffective disorders?
    Psychiatry Res. 2022;316:114726.
    PubMed     Abstract available

  45. PARK HJ, Kang WS, Oh M, Kim JW, et al
    Association of the promoter haplotype in CDK5 gene with schizophrenia in a Korean population.
    Psychiatry Res. 2022;316:114723.

  46. RIBOLSI M, Albergo G, Fiori Nastro F, Pelle M, et al
    Autistic symptomatology in UHR patients: A preliminary report.
    Psychiatry Res. 2022;313:114634.
    PubMed     Abstract available

  47. NGUYEN T, Frayne J, Watson S, Lebedevs T, et al
    Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospital.
    Psychiatry Res. 2022;313:114614.
    PubMed     Abstract available

    June 2022
  48. DIAGO M, Vila-Badia R, Serra-Arumi C, Butjosa A, et al
    Emotional abuse and perceived stress: The most relevant factors in suicide behavior in first-episode psychosis patients.
    Psychiatry Res. 2022;315:114699.
    PubMed     Abstract available

  49. JEREMIAN R, Malinowski A, Chaudhary Z, Srivastava A, et al
    Epigenetic age dysregulation in individuals with bipolar disorder and schizophrenia.
    Psychiatry Res. 2022;315:114689.
    PubMed     Abstract available

  50. RAMAIN J, Conus P, Golay P
    Grouping affective psychoses in early intervention: Justification for specific treatment guidelines.
    Psychiatry Res. 2022;314:114690.
    PubMed     Abstract available

  51. ZARBO C, Agosta S, Casiraghi L, De Novellis A, et al
    Assessing adherence to and usability of Experience Sampling Method (ESM) and actigraph in patients with Schizophrenia Spectrum Disorder: A mixed-method study.
    Psychiatry Res. 2022;314:114675.
    PubMed     Abstract available

    May 2022
  52. LI Z, Li X, Jin M, Liu Y, et al
    Identification of potential biomarkers and their correlation with immune infiltration cells in schizophrenia using combinative bioinformatics strategy.
    Psychiatry Res. 2022;314:114658.
    PubMed     Abstract available

  53. SHIMADA T, Ito S, Makabe A, Yamanushi A, et al
    Aerobic exercise and cognitive functioning in schizophrenia: An updated systematic review and meta-analysis.
    Psychiatry Res. 2022;314:114656.
    PubMed     Abstract available

  54. KIRSCHENBAUM MA, Lopez LV, de Filippis R, Ali AF, et al
    Validation of a novel Psychosis-Implicit Association Test (P-IAT) as a diagnostic support tool.
    Psychiatry Res. 2022;314:114647.
    PubMed     Abstract available

  55. BHATTACHARYYA U, Bhatia T, Deshpande SN, Thelma BK, et al
    Genetic variations in evolutionary accelerated regions disrupt cognition in schizophrenia.
    Psychiatry Res. 2022;314:114586.
    PubMed     Abstract available

  56. XU L, Hao D, Wei Y, Cui H, et al
    Effect of cognitive insight on clinical insight from pre-morbid to early psychosis stages.
    Psychiatry Res. 2022;313:114613.
    PubMed     Abstract available

  57. CAO X, Chen S, Xu H, Wang Q, et al
    Global functioning, cognitive function, psychopathological symptoms in untreated patients with first-episode schizophrenia: A cross-sectional study.
    Psychiatry Res. 2022;313:114616.
    PubMed     Abstract available

  58. LONG J, Tian L, Baranova A, Cao H, et al
    Convergent lines of evidence supporting involvement of NFKB1 in schizophrenia.
    Psychiatry Res. 2022;312:114588.
    PubMed     Abstract available

  59. KATZ IR, Szymanski BR, Marder SR, Shotwell A, et al
    Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications.
    Psychiatry Res. 2022;313:114590.
    PubMed     Abstract available

    April 2022
  60. THAI H, Robertson C, Friberg L, Hatko A, et al
    WHODAS 2.0: Associations of functional disability with sex, age, and length of care in outpatients with schizophrenia-spectrum disorders.
    Psychiatry Res. 2022;313:114583.
    PubMed     Abstract available

  61. MARTINS PS, Caldas F, Oliveira C, Mota J, et al
    A 10-year mirror-image study of effectiveness and cost of long-acting paliperidone palmitate injectable in patients with schizophrenia or schizoaffective disorder.
    Psychiatry Res. 2022;312:114581.
    PubMed     Abstract available

  62. LI X, Yuan X, Pang L, Zhang S, et al
    nThe effect of serum lipids and short-chain fatty acids on cognitive functioning in drug-naive, first episode schizophrenia patients.
    Psychiatry Res. 2022;313:114582.
    PubMed     Abstract available

  63. XU Y, Cai Z, Fang C, Zheng J, et al
    Impact of aerobic exercise on cognitive function in patients with schizophrenia during daily care: A meta-analysis.
    Psychiatry Res. 2022;312:114560.
    PubMed     Abstract available

  64. OUYANG H, Huang M, Chen S, Wu X, et al
    Peripheral lower triiodothyronine levels related to interleukin-6 in patients with first-episode schizophrenia.
    Psychiatry Res. 2022;312:114546.

  65. WELCH KG, Stiles BJ, Palsson OS, Meyer-Kalos PS, et al
    The use of diary methods to evaluate daily experiences in first-episode psychosis.
    Psychiatry Res. 2022;312:114548.
    PubMed     Abstract available

  66. GONZALEZ-RODRIGUEZ A, Monreal JA, Porras-Segovia A, Cervilla JA, et al
    Psychometric instruments for the assessment of depressive symptoms in patients with delusional disorder: A systematic review.
    Psychiatry Res. 2022;310:114435.
    PubMed     Abstract available

    March 2022
  67. JAISWAL N, Kar SK, Gupta PK
    Comments on "High frequency repetitive transcranial magnetic stimulation of dorsomedial prefrontal cortex for negative symptoms in patients with schizophrenia: A double-blind, randomized controlled trial".
    Psychiatry Res. 2022;312:114532.

  68. PANDOLFO G, Genovese G, Bruno A, Campolo D, et al
    Advanced glycation end-products and advanced oxidation protein products in schizophrenia.
    Psychiatry Res. 2022;311:114527.
    PubMed     Abstract available

  69. LI J, Zhang X, Jiang J, Zhang B, et al
    Comparison of electroconvulsive therapy and magnetic seizure therapy in schizophrenia: Structural changes/neuroplasticity.
    Psychiatry Res. 2022;312:114523.
    PubMed     Abstract available

  70. BORNHEIMER LA, Li Verdugo J, Holzworth J, Im V, et al
    Modifying a cognitive behavioral suicide prevention treatment for adults with schizophrenia spectrum disorders in community mental health.
    Psychiatry Res. 2022;311:114505.
    PubMed     Abstract available

  71. XU X, Shao G, Zhang X, Hu Y, et al
    The efficacy of nutritional supplements for the adjunctive treatment of schizophrenia in adults: A systematic review and network meta-analysis.
    Psychiatry Res. 2022;311:114500.
    PubMed     Abstract available

  72. RAMMOUZ I, Bouri S, Merzouki M, Berraho MA, et al
    Reliability of self-report of cannabis use among patients with schizophrenia.
    Psychiatry Res. 2022;311:114491.

  73. KEMPPAINEN A, Lindgren M, Suvisaari J, Kieseppa T, et al
    Adverse childhood experiences and social and occupational functioning in first-episode psychosis - A one year follow - up.
    Psychiatry Res. 2022;311:114502.

  74. MUNIR K, Oner O, Kerala C, Rustamov I, et al
    Social distance and stigma towards persons with serious mental illness among medical students in five European Central Asia countries.
    Psychiatry Res. 2022;309:114409.
    PubMed     Abstract available

    February 2022
  75. GOHARI E, Moore RC, Depp CA, Ackerman RA, et al
    Momentary severity of psychotic symptoms predicts overestimation of competence in domains of everyday activities and work in schizophrenia: An ecological momentary assessment study.
    Psychiatry Res. 2022;310:114487.
    PubMed     Abstract available

  76. LIU Y, Jia LN, Wu H, Jiang W, et al
    Adjuvant electroconvulsive therapy with antipsychotics is associated with improvement in auditory mismatch negativity in schizophrenia.
    Psychiatry Res. 2022;311:114484.

  77. COWAN T, Cohen AS, Raugh IM, Strauss GP, et al
    Ambulatory audio and video recording for digital phenotyping in schizophrenia: Adherence & data usability.
    Psychiatry Res. 2022;311:114485.
    PubMed     Abstract available

  78. SANTESTEBAN-ECHARRI O, Sandel D, Liu L, Bearden CE, et al
    Family history of psychosis in youth at clinical high risk: A replication study.
    Psychiatry Res. 2022;311:114480.
    PubMed     Abstract available

  79. MORIKAWA R, Watanabe Y, Igeta H, Arta RK, et al
    Novel missense SETD1A variants in Japanese patients with schizophrenia: Resequencing and association analysis.
    Psychiatry Res. 2022;310:114481.
    PubMed     Abstract available

  80. RODRIGUEZ M, Knizkova K, Kerkova B, Sironova A, et al
    The relationships between cognitive reserve, cognitive functioning and quality of life in first-episode schizophrenia spectrum disorders.
    Psychiatry Res. 2022;310:114479.
    PubMed     Abstract available

  81. LEE HS, Rast C, Shenoy S, Dean D, et al
    A meta-analytic review of transcranial direct current stimulation (tDCS) on general psychopathology symptoms of schizophrenia; immediate improvement followed by a return to baseline.
    Psychiatry Res. 2022;310:114471.
    PubMed     Abstract available

  82. SONG W, Lin GN, Yu S, Zhao M, et al
    Genome-wide identification of the shared genetic basis of cannabis and cigarette smoking and schizophrenia implicates NCAM1 and neuronal abnormality.
    Psychiatry Res. 2022;310:114453.
    PubMed     Abstract available

  83. TAN EJ, Toh WL, Rossell SL
    Examining relationships between state and trait psychotic symptoms and quality of life in schizophrenia spectrum disorders.
    Psychiatry Res. 2022;310:114450.
    PubMed     Abstract available

  84. LOPEZ-NAVARRO E, Fonseca-Pedrero E, Errasti J, Al-Halabi S, et al
    Mindfulness improves theory of mind in people experiencing psychosis: A pilot randomized clinical trial.
    Psychiatry Res. 2022;310:114440.
    PubMed     Abstract available

  85. GOH XX, Tang PY, Tee SF
    Effects of antipsychotics on antioxidant defence system in patients with schizophrenia: A meta-analysis.
    Psychiatry Res. 2022;309:114429.
    PubMed     Abstract available

  86. SCHWARTZ EK, Le TP, Cohen AS
    Sharing positive events: Ecological momentary assessment of emotion regulation via social capitalization in schizotypy.
    Psychiatry Res. 2022;308:114377.
    PubMed     Abstract available

  87. GROENMAN AP, van der Werf S, Geurts HM
    Subjective cognition in adults with common psychiatric classifications; a systematic review.
    Psychiatry Res. 2022;308:114374.
    PubMed     Abstract available

    January 2022
  88. JEONG JH, Kim SW, Lee BJ, Kim JJ, et al
    The factor structure and clinical utility of clinician-rated dimensions of psychosis symptom severity in patients with recent-onset psychosis: Results of a 1-year longitudinal follow-up prospective cohort study.
    Psychiatry Res. 2022;310:114420.
    PubMed     Abstract available

  89. BARTOLI F, Cavaleri D, Callovini T, Riboldi I, et al
    Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study.
    Psychiatry Res. 2022;309:114405.
    PubMed     Abstract available

  90. LUNDIN NB, Jones MN, Myers EJ, Breier A, et al
    Semantic and phonetic similarity of verbal fluency responses in early-stage psychosis.
    Psychiatry Res. 2022;309:114404.
    PubMed     Abstract available

  91. XIE Y, He Y, Guan M, Wang Z, et al
    Low-frequency rTMS treatment alters the topographical organization of functional brain networks in schizophrenia patients with auditory verbal hallucination.
    Psychiatry Res. 2022;309:114393.
    PubMed     Abstract available

  92. RAULT O, Lamothe H, Pelissolo A
    Therapeutic use of virtual reality relaxation in schizophrenia: A pilot study.
    Psychiatry Res. 2022;309:114389.
    PubMed     Abstract available

  93. VERDOUX H, Sibert A, Quiles C
    Trauma and resistance to antipsychotic treatment in schizophrenia: A narrative review.
    Psychiatry Res. 2022;309:114392.
    PubMed     Abstract available

  94. MORAN LV, Tsang ES, Ongur D, Hsu J, et al
    Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States: Submit to: Psychiatry Research.
    Psychiatry Res. 2022;308:114387.
    PubMed     Abstract available

  95. SINGH A, Kumar V, Pathak H, Jacob AA, et al
    Effect of antipsychotic dose reduction on cognitive function in schizophrenia.
    Psychiatry Res. 2022;308:114383.
    PubMed     Abstract available

  96. GANDHI A, Mote J, Fulford D
    A transdiagnostic meta-analysis of physical and social Anhedonia in major depressive disorder and schizophrenia spectrum disorders.
    Psychiatry Res. 2022;309:114379.
    PubMed     Abstract available

    December 2021
  97. LABONTE C, Zhand N, Park A, Harvey PD, et al
    Complete blood count inflammatory markers in treatment-resistant schizophrenia: Evidence of association between treatment responsiveness and levels of inflammation.
    Psychiatry Res. 2021;308:114382.
    PubMed     Abstract available

  98. GICAS KM, Parmar PK, Fabiano GF, Mashhadi F, et al
    Substance-induced psychosis and cognitive functioning: A systematic review.
    Psychiatry Res. 2021;308:114361.
    PubMed     Abstract available

  99. GARRIDO-TORRES N, Suarez-Suarez ML, Rocha-Gonzalez I, Alameda L, et al
    Higher rates of first episode psychosis in immigrants admitted in inpatient unit at southwest Spain.
    Psychiatry Res. 2021;308:114352.
    PubMed     Abstract available

  100. VERU F, MacDonald K, Malla A, Pruessner M, et al
    The effects of childhood adversity on treatment delays and its components in first-episode psychosis.
    Psychiatry Res. 2021;308:114341.
    PubMed     Abstract available

  101. LAVAUD P, McMahon K, Sanchez Rico M, Hanon C, et al
    Long-term care utilization within older adults with schizophrenia: Associated factors in a multicenter study.
    Psychiatry Res. 2021;308:114339.
    PubMed     Abstract available

  102. LIU X, Wang D, Fan R, Wang R, et al
    Life expectancy and potential years of life lost for schizophrenia in western China.
    Psychiatry Res. 2021;308:114330.
    PubMed     Abstract available

  103. LOCKWOOD L, Miller B, Youssef NA
    Epigenetics and first-episode psychosis: A systematic review.
    Psychiatry Res. 2021;307:114325.
    PubMed     Abstract available

  104. THOMPSON EC, Visser KF, Schiffman J, Spirito A, et al
    Preliminary evidence supporting the practice of psychosis-risk screening within an inpatient psychiatric setting serving adolescents.
    Psychiatry Res. 2021;307:114322.
    PubMed     Abstract available

  105. LEE S, Schwartz S
    Adherence and persistence to long-acting injectable dopamine receptor blocking agent therapy in the United States: A systematic review and meta-analysis of cohort studies.
    Psychiatry Res. 2021;306:114277.
    PubMed     Abstract available

    November 2021
  106. LOCH AA, Mota NB, Rossler W, Gattaz WF, et al
    Exacerbation of psychosis risk during the COVID-19 pandemic: The disproportionate impact on the lower income population.
    Psychiatry Res. 2021;307:114319.

  107. ALLIENDE LM, Czepielewski LS, Aceituno D, Castaneda CP, et al
    Gender, age and geographical representation over the past 50 years of schizophrenia research.
    Psychiatry Res. 2021;307:114279.
    PubMed     Abstract available

  108. FERNANDEZ DK, Deane FP, Vella SA
    Effects of online continuum and categorical belief manipulations on schizophrenia stigma, help-seeking, and help-provision.
    Psychiatry Res. 2021;307:114293.
    PubMed     Abstract available

  109. CHEN S, Tang Y, Fan X, Qiao Y, et al
    The role of white matter abnormality in the left anterior corona radiata: In relation to formal thought disorder in patients with schizophrenia.
    Psychiatry Res. 2021;307:114302.
    PubMed     Abstract available

  110. GOU N, Xiang Y, Zhou J, Zhang S, et al
    Identification of violent patients with schizophrenia using a hybrid machine learning approach at the individual level.
    Psychiatry Res. 2021;306:114294.
    PubMed     Abstract available

  111. LAI M, Hegde R, Kelly S, Bannai D, et al
    Investigating sleep spindle density and schizophrenia: A meta-analysis.
    Psychiatry Res. 2021;307:114265.
    PubMed     Abstract available

  112. BARR SM, Roberts D, Thakkar KN
    Psychosis in transgender and gender non-conforming individuals: A review of the literature and a call for more research.
    Psychiatry Res. 2021;306:114272.
    PubMed     Abstract available

  113. LYU J, Zhang J
    Suicide means, timing, intent and behavior characteristics of the suicides with schizophrenia.
    Psychiatry Res. 2021;306:114267.
    PubMed     Abstract available

  114. RUSSO M, Consoli S, De Rosa MA, Calisi D, et al
    A case of Sars-Cov-2-related mania with prominent psychosis>.
    Psychiatry Res. 2021;306:114266.

  115. GALLOS IK, Mantonakis L, Spilioti E, Kattoulas E, et al
    The relation of integrated psychological therapy to resting state functional brain connectivity networks in patients with schizophrenia.
    Psychiatry Res. 2021;306:114270.
    PubMed     Abstract available

  116. SANTOS MJ, Ferreira TF, Sequeira M, Trancas B, et al
    Chronic hallucinatory psychosis presenting with olfactory hallucinations: A case report.
    Psychiatry Res. 2021;305:114262.

  117. SAHYOUNI C, Hefazi E
    Clozapine induced pericarditis: A case report.
    Psychiatry Res. 2021;305:114250.
    PubMed     Abstract available

  118. SHROITMAN NK, Peles E, Even-Tov S, Schreiber S, et al
    False-positive fentanyl screening kit results during treatment with long term injectable risperidone (Risperdal-Consta).
    Psychiatry Res. 2021;305:114246.
    PubMed     Abstract available

  119. RICHARDSON N, Greenway SC, Bousman CA
    Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: A systematic case review.
    Psychiatry Res. 2021;305:114247.
    PubMed     Abstract available

  120. BRASSO C, Cisotto M, Ghirardini C, Pennazio F, et al
    Accuracy of self-reported adherence and therapeutic drug monitoring in a psychiatric emergency ward.
    Psychiatry Res. 2021;305:114214.
    PubMed     Abstract available

  121. GROT S, Giguere CE, Smine S, Mongeau-Perusse V, et al
    Converting scores between the PANSS and SAPS/SANS beyond the positive/negative dichotomy.
    Psychiatry Res. 2021;305:114199.
    PubMed     Abstract available

  122. MILLER BJ, McCall WV, McEvoy JP, Lu XY, et al
    Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
    Psychiatry Res. 2021;305:114195.
    PubMed     Abstract available

    October 2021
  123. MENON V, Suhas S, Sethi MIS, Varadharajan N, et al
    Comments on the paper published by Lyu et al on Risk Factors for Suicide in People with Schizophrenia.
    Psychiatry Res. 2021;306:114255.

  124. DAMIANO RF, Avrichir BS, Melzer-Ribeiro DL, Sallet PC, et al
    Which are the best evidence-based therapeutic options for clozapine and ECT resistant schizophrenia? A case-report.
    Psychiatry Res. 2021;305:114248.
    PubMed     Abstract available

  125. PAWELCZYK A, Lojek E, Radek M, Pawelczyk T, et al
    Prosodic deficits and interpersonal difficulties in patients with schizophrenia.
    Psychiatry Res. 2021;306:114244.
    PubMed     Abstract available

  126. LUO X, Zhang L, Zhang J, Chen H, et al
    Changes in the cognitive function of Chinese college students with a clinical high risk of psychosis.
    Psychiatry Res. 2021;305:114242.
    PubMed     Abstract available

  127. CLAYSON PE, Molina JL, Joshi YB, Thomas ML, et al
    Evaluation of the frequency following response as a predictive biomarker of response to cognitive training in schizophrenia.
    Psychiatry Res. 2021;305:114239.
    PubMed     Abstract available

  128. JIANG W, Rootes-Murdy K, Chen J, Bizzozero NIP, et al
    Multivariate alterations in insula - Medial prefrontal cortex linked to genetics in 12q24 in schizophrenia.
    Psychiatry Res. 2021;306:114237.
    PubMed     Abstract available

  129. SANCHEZ MC, Escurriola MF, Sanmartin MIF, Solntseva I, et al
    Cardiovascular disease and mortality in people with schizophrenia or antipsychotic treatment: A cohort study in primary care.
    Psychiatry Res. 2021;306:114233.
    PubMed     Abstract available

  130. BRYCE S, Zbukvic I, Wood SJ, Allott K, et al
    Cognitive remediation to address impairment in schizophrenia: Moving beyond effectiveness and toward implementation.
    Psychiatry Res. 2021;305:114232.

  131. MINICHINO A, Singh F, Pineda J, Friederich E, et al
    Corrigendum to 'Biological Motion induced mu suppression is reduced in Early Psychosis (EP) patients with active negative symptoms and Autism Spectrum Disorders (ASD)' [Psychiatry Research 238 (2016) 374-377].
    Psychiatry Res. 2021;306:114177.

  132. SARZYNSKA-WAWER J, Wawer A, Pawlak A, Szymanowska J, et al
    Detecting formal thought disorder by deep contextualized word representations.
    Psychiatry Res. 2021;304:114135.
    PubMed     Abstract available

    September 2021
  133. LUDTKE T, Ruegg N, Moritz S, Berger T, et al
    Insight and the number of completed modules predict a reduction of positive symptoms in an Internet-based intervention for people with psychosis.
    Psychiatry Res. 2021;306:114223.
    PubMed     Abstract available

  134. ZOU DS, Cowan HR, Azis M, Mittal VA, et al
    Reciprocal Social Behavior and Related Social Outcomes in Individuals at Clinical High Risk for Psychosis.
    Psychiatry Res. 2021;306:114224.
    PubMed     Abstract available

  135. SRIVASTAVA A, Dada O, Qian J, Al-Chalabi N, et al
    Epigenetics of Schizophrenia.
    Psychiatry Res. 2021;305:114218.
    PubMed     Abstract available

  136. FERNANDO R, Gan L, Xiao J, Yun Y, et al
    Hyperprolactinemia induced by brexpiprazole in patients with schizophrenia: A case report.
    Psychiatry Res. 2021;305:114215.

  137. HOMMAN LE, Smart SE, O'Neill F, MacCabe JH, et al
    Attrition in longitudinal studies among patients with schizophrenia and other psychoses; findings from the STRATA collaboration.
    Psychiatry Res. 2021;305:114211.
    PubMed     Abstract available

  138. MISHRA A, Soni AB, Umate MS, Andrade C, et al
    An exploratory evaluation of predictors of duration of untreated psychosis in first-episode psychosis in lower income patients.
    Psychiatry Res. 2021;305:114203.
    PubMed     Abstract available

  139. ZHU L, Zhang W, Zhu Y, Mu X, et al
    Cerebellar theta burst stimulation for the treatment of negative symptoms of schizophrenia: A multicenter, double-blind, randomized controlled trial.
    Psychiatry Res. 2021;305:114204.
    PubMed     Abstract available

  140. SHOSHINA II, Hovis JK, Felisberti FM, Santos NA, et al
    Visual processing and BDNF levels in first-episode schizophrenia.
    Psychiatry Res. 2021;305:114200.
    PubMed     Abstract available

  141. RABINOWITZ J, Rabinowitz AA
    Outlier-response pattern checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS).
    Psychiatry Res. 2021;303:114114.
    PubMed     Abstract available

  142. VALERIO KE, Jonas KG, Perlman G, Bromet EJ, et al
    A comparison of cognitive performance in the Suffolk County cohort and their unaffected siblings.
    Psychiatry Res. 2021;303:114111.
    PubMed     Abstract available

    August 2021
  143. KARTALCI S, Erbay MF, Kahraman A, Candir F, et al
    Evaluation of CSF flow dynamics in patients with schizophrenia using phase-contrast cine MRI.
    Psychiatry Res. 2021;304:114172.
    PubMed     Abstract available

  144. REINFELD S, Caceda R, Gil R, Strom H, et al
    Can new onset psychosis occur after mRNA based COVID-19 vaccine administration? A case report.
    Psychiatry Res. 2021;304:114165.

  145. LYU J, Zhang J, Hennessy DA
    Characteristics and Risk Factors for Suicide in People with Schizophrenia in Comparison to Those without Schizophrenia.
    Psychiatry Res. 2021;304:114166.
    PubMed     Abstract available

  146. YANG H, Xiao W, Yang M, Wang Y, et al
    Decreased neuregulin1beta1 in first episode and drug-naive patients with schizophrenia: Negative correlation with cognitive impairment.
    Psychiatry Res. 2021;304:114164.
    PubMed     Abstract available

  147. SAHIN D, Hever F, Bossert M, Herwig K, et al
    Early and middle latency auditory event-related potentials do not explain differences in neuropsychological performance between schizophrenia spectrum patients and matched healthy controls.
    Psychiatry Res. 2021;304:114162.
    PubMed     Abstract available

  148. DAURE C, Fortias M, Icick R, Delage C, et al
    Oral long acting antipsychotic penfluridol as a harm reduction treatment in a patient suffering from untreated schizophrenia and multiple drug dependence: A case report.
    Psychiatry Res. 2021;304:114147.
    PubMed     Abstract available

    July 2021
  149. DA MOTTA C, Pato MT, Barreto Carvalho C, Castilho P, et al
    The neurocognitive and functional profile of schizophrenia in a genetically homogenous European sample.
    Psychiatry Res. 2021;304:114140.
    PubMed     Abstract available

  150. VOPPEL AE, de Boer JN, Brederoo SG, Schnack HG, et al
    Quantified language connectedness in schizophrenia-spectrum disorders.
    Psychiatry Res. 2021;304:114130.
    PubMed     Abstract available

  151. BOSNJAK KUHARIC D, Makaric P, Kekin I, Rossini Gajsak L, et al
    Changes of neurocognitive status in patients with the first-episode psychosis after 18 months of treatment-A prospective cohort study.
    Psychiatry Res. 2021;304:114131.
    PubMed     Abstract available

  152. GRACIA DFK, Gomes EMP, Coelho TA, Carriello M, et al
    Ficolin activation as a potential biomarker of the severity of schizophrenia.
    Psychiatry Res. 2021;304:114122.
    PubMed     Abstract available

  153. KU BS, Pauselli L, Covington MA, Compton MT, et al
    Computational linguistic analysis applied to a semantic fluency task: A replication among first-episode psychosis patients with and without derailment and tangentiality.
    Psychiatry Res. 2021;304:114105.
    PubMed     Abstract available

  154. SNELLEKSZ M, Dean B
    Lower levels of tubulin alpha 1b in the frontal pole in schizophrenia supports a role for changed cytoskeletal dynamics in the aetiology of the disorder.
    Psychiatry Res. 2021;303:114096.
    PubMed     Abstract available

  155. VASKINN A, Engelstad KN, Torgalsboen AK, Rund BR, et al
    Childhood trauma, social cognition and schizophrenia: Specific association between physical neglect and cognitive theory of mind in homicide offenders.
    Psychiatry Res. 2021;303:114093.
    PubMed     Abstract available

  156. JAGADHEESAN K, Danivas V, Itrat Q, Shekaran L, et al
    A 6-month study on the pattern of emergency department presentations for schizophrenia and other psychotic disorders during COVID-19 lockdown.
    Psychiatry Res. 2021;303:114081.
    PubMed     Abstract available

    June 2021
  157. CORBERA S, Wexler BE, Bell MD, Pearlson G, et al
    Predictors of social functioning and quality of life in schizophrenia and autism spectrum disorder.
    Psychiatry Res. 2021;303:114087.
    PubMed     Abstract available

  158. LI S, DeLisi LE, McDonough SI
    Rare germline variants in individuals diagnosed with schizophrenia within multiplex families.
    Psychiatry Res. 2021;303:114038.
    PubMed     Abstract available

  159. CASADO-ORTEGA A, Vila-Badia R, Butjosa A, Del Cacho N, et al
    Social cognition and its relationship with sociodemographic, clinical, and psychosocial variables in first-episode psychosis.
    Psychiatry Res. 2021;302:114040.
    PubMed     Abstract available

  160. ANDREOU D, Jorgensen KN, Wortinger LA, Engen K, et al
    Cytomegalovirus infection and IQ in patients with severe mental illness and healthy individuals.
    Psychiatry Res. 2021;300:113929.
    PubMed     Abstract available

  161. BRAUN D, Schlossmann J, Haen E
    Asymmetric dimethylarginine in psychiatric disorders.
    Psychiatry Res. 2021;300:113901.
    PubMed     Abstract available

    May 2021
  162. KELLY DL, Claxton A, Bidollari I, Du Y, et al
    Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
    Psychiatry Res. 2021;302:114030.
    PubMed     Abstract available

  163. GUILLAUME F, Thomas E
    Recollection and familiarity in schizophrenia:An ERP investigation using face recognition exclusion tasks.
    Psychiatry Res. 2021;302:113973.
    PubMed     Abstract available

  164. SCHEFFLER F, Phahladira L, Luckhoff H, du Plessis S, et al
    Cannabis use and clinical outcome in people with first-episode schizophrenia spectrum disorders over 24 months of treatment.
    Psychiatry Res. 2021;302:114022.
    PubMed     Abstract available

  165. MUNOZ-SAMONS D, Tor J, Rodriguez-Pascual M, Alvarez-Subiela X, et al
    Recent stressful life events and stress sensitivity in children and adolescents at clinical risk for psychosis.
    Psychiatry Res. 2021;303:114017.
    PubMed     Abstract available

  166. HELLER C, Weiss T, Del Re EC, Swago S, et al
    Smaller subcortical volumes and enlarged lateral ventricles are associated with higher global functioning in young adults with 22q11.2 deletion syndrome with prodromal symptoms of schizophrenia.
    Psychiatry Res. 2021;301:113979.
    PubMed     Abstract available

  167. ABEL DB, Salyers MP, Wu W, Monette MA, et al
    Quality versus quantity: Determining real-world social functioning deficits in schizophrenia.
    Psychiatry Res. 2021;301:113980.
    PubMed     Abstract available

    April 2021
  168. ALBA L, Coll C, Saez S, Alonso L, et al
    New-onset psychosis: A case report of brief psychosis related to COVID-19 infection.
    Psychiatry Res. 2021;301:113975.

  169. UCOK A, Karakas B, Sahin OS
    Formal thought disorder in patients with first-episode schizophrenia: Results of a one-year follow-up study.
    Psychiatry Res. 2021;301:113972.
    PubMed     Abstract available

  170. Discrepancies between staff and gold standard ratings of schizophrenia symptom severity.
    Psychiatry Res. 2021;301:113963.

  171. DE PERI L, Deste G, Vita A
    Strucutural brain imaging at the onset of schizophrenia:What have we learned and what have we missed.
    Psychiatry Res. 2021;301:113962.
    PubMed     Abstract available

  172. MEDALIA A, Saperstein AM, Stefancic A, Meyler S, et al
    Feasibility and acceptability of remotely accessed cognitive remediation for schizophrenia in public health settings.
    Psychiatry Res. 2021;301:113956.
    PubMed     Abstract available

  173. XIE YJ, Xi YB, Cui LB, Guan MZ, et al
    Functional connectivity of cerebellar dentate nucleus and cognitive impairments in patients with drug-naive and first-episode schizophrenia.
    Psychiatry Res. 2021;300:113937.
    PubMed     Abstract available

  174. PENNOU A, Lecomte T, Khazaal Y, Potvin S, et al
    Does theory of mind predict specific domains of social functioning in individuals following a first episode psychosis?
    Psychiatry Res. 2021;301:113933.
    PubMed     Abstract available

  175. WANG YY, Hsu SH, Tsai HY, Cheng MC, et al
    Sequencing of the coding regions of GNBIL on chromosome 22q11.2 as a risk gene of schizophrenia.
    Psychiatry Res. 2021;300:113943.
    PubMed     Abstract available

  176. SCHURHOFF F, Corfdir C, Pignon B, Lajnef M, et al
    No alteration of leukocyte telomere length in first episode psychosis.
    Psychiatry Res. 2021;301:113941.
    PubMed     Abstract available

  177. VAERNES TG, Rossberg JI, Melle I, Nelson B, et al
    Basic self-disturbance in subjects at clinical high risk for psychosis: Relationship with clinical and functional outcomes at one year follow-up.
    Psychiatry Res. 2021;300:113942.
    PubMed     Abstract available

  178. STRASSNIG MT, Miller ML, Moore R, Depp CA, et al
    Evidence for avolition in bipolar disorder? A 30-day ecological momentary assessment comparison of daily activities in bipolar disorder and schizophrenia.
    Psychiatry Res. 2021;300:113924.
    PubMed     Abstract available

  179. SIDDIQUI SV, Nizamie SH, Siddiqui MA, Jahan M, et al
    Evaluation of N-400 Evoked Response Potential in schizophrenia: An endophenotype or a disease marker?
    Psychiatry Res. 2021;300:113907.
    PubMed     Abstract available

    March 2021
  180. AU RWC, Sezto HNW, Lam VWM, Wan YT, et al
    Brief report: A randomized controlled trial of a compensatory cognitive training to improve prospective memory performance in people with schizophrenia or depression.
    Psychiatry Res. 2021;300:113914.
    PubMed     Abstract available

  181. LI M, Liu Y, Qiu Y, Zhang J, et al
    The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
    Psychiatry Res. 2021;300:113899.
    PubMed     Abstract available

  182. SIMON AE, Keller P, Cattapan K
    Commentary about social avoidance and its significance in adolescents and young adults.
    Psychiatry Res. 2021;297:113718.
    PubMed     Abstract available

  183. TOYODA K, Hata T, Yamauchi S, Kinoshita S, et al
    A descriptive study of 10-year clozapine use from the nationwide database in Japan.
    Psychiatry Res. 2021;297:113764.
    PubMed     Abstract available

  184. O'CONNOR C, Vaughan S
    Does selectively endorsing different approaches to treating mental illness affect lay beliefs about the cause and course of mental illness?
    Psychiatry Res. 2021;297:113726.
    PubMed     Abstract available

    February 2021
  185. SREERAJ VS, Holla B, Ithal D, Nadella RK, et al
    Psychiatric symptoms and syndromes transcending diagnostic boundaries in Indian multiplex families: The cohort of ADBS study.
    Psychiatry Res. 2021;296:113647.
    PubMed     Abstract available

  186. MORRIS E, Batallones R, Ryan J, Slomp C, et al
    Psychiatric genetic counseling for serious mental illness: Impact on psychopathology and psychotropic medication adherence.
    Psychiatry Res. 2021;296:113663.
    PubMed     Abstract available

  187. CAMUS D, Dan Glauser ES, Gholamrezaee M, Gasser J, et al
    Factors associated with repetitive violent behavior of psychiatric inpatients.
    Psychiatry Res. 2021;296:113643.
    PubMed     Abstract available

  188. GURCAN G, Senol SH, Yagcioglu AEA, Ertugrul A, et al
    Clinical risk factors, phenomenology and the impact of clozapine induced obsessive compulsive symptoms.
    Psychiatry Res. 2021;296:113665.
    PubMed     Abstract available

  189. KHARE C, Mueser KT, Bahaley M, Vax S, et al
    Employment in people with severe mental illnesses receiving public sector psychiatric services in India.
    Psychiatry Res. 2021;296:113673.
    PubMed     Abstract available

    January 2021
  190. KETHARANATHAN T, Pereira A, Reets U, Walker D, et al
    Brain changes in NF-kappaB1 and epidermal growth factor system markers at peri-pubescence in the spiny mouse following maternal immune activation.
    Psychiatry Res. 2021;295:113564.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.